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molecular clinical case
New mutation in the CASR gene in 
a family with familial hypocalciuric 
hypercalcemia (FHH) and neonatal 
severe hyperparathyroidism (NSHPT)
Nova mutação no gene CASR em uma família 
com hipercalcemia hipocalciúrica familiar (HHF) e 
hiperparatireoidismo neonatal grave (HPTNG)
Luiza Souza Rodrigues1, Ana Carolina Arias Cáu2,  
Luciane Zgoda Bussmann1, Gabriela Bastida2, Oscar H. Brunetto2, 
Pedro Henrique Silveira Corrêa3, Regina Matsunaga Martin3
SUMMARY
A loss of calcium-sensing receptor (CASR) function due to inactivating mutations can cause 
familial hypocalciuric hypercalcemia (FHH) or neonatal severe hyperparathyroidism (NSHPT). 
NSHPT represents the most severe expression of FHH and courses as a life-threatening condi-
tion. The aim of this study was to identify and characterize a CASR mutation in a female infant 
brought to the health service due to dehydration, apathy, lack of breast feeding and severe 
hypercalcemia. Molecular analysis was performed on genomic DNA of the index case and her 
parents. A novel homozygous mutation (p.E519X) in CASR was identified in the proband; both 
mother and father had the same mutation in heterozygous state, confirming their FHH condi-
tion. The mutation results in a truncated and inactive protein due to the lack of transmembrane 
and intracellular domains. The identification of this novel CASR gene mutation established the 
basis of hypercalcemia in this family and allowed a genetic counseling. Arq Bras Endocrinol Metab. 
2011;55(1):67-71
SUMÁRIO
Mutações inativadoras no gene do sensor do cálcio (CASR) podem causar hipercalcemia hi-
pocalciúrica familiar (HHF) ou hiperparatireoidismo neonatal grave (HPTNSG). A HPTNS re-
presenta a forma mais grave da HHF cursando com risco de vida. O objetivo deste estudo foi 
identificar e caracterizar uma mutação no gene CASR de uma criança do sexo feminino levada 
ao hospital em decorrência de desidratação, apatia, dificuldade para mamar e hipercalcemia 
grave. A análise molecular foi realizada a partir do DNA genômico do caso índice e de seus 
pais. Uma nova mutação em homozigose (p.E519X) foi identificada no caso índice; ambos, mãe 
e pai, apresentaram a mesma mutação em heterozigose, o que os caracteriza como portadores 
de HHF. Essa alteração resulta em uma proteína truncada e inativa devido à falta dos domínios 
transmembrana e intracelular. A identificação dessa nova mutação estabeleceu a causa da hi-
percalcemia na família e permitiu o aconselhamento genético. Arq Bras Endocrinol Metab. 2011;55(1):67-71
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INTRODUCTION
The calcium sensing receptor (CASR) is a G-protein coupled receptor well expressed in parathyroid and 
renal tubule cells that plays an essential role in calcium 
homeostasis. About 200 mutations have previously 
been described in the CASR gene which result in loss 
or gain of function. The most common are missense 
mutations. Familial hypocalciuric hypercalcemia (FHH) 
and neonatal severe hyperparathyroidism (NSHPT) 
can be associated with loss of CASR function. The first 
condition is an autosomal dominant disease character-
ized by mild elevations of serum calcium concentration, 
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Novel calcium-sensing receptor mutation
lower urinary calcium, excretion and inappropriately 
normal PTH levels. Individuals with FHH are usually 
asymptomatic and the disorder is considered benign. 
NSHPT represents the most severe expression of FHH 
and courses as a life-threatening condition with severe 
hypercalcemia, hypotonia, bone demineralization, frac-
tures, and respiratory distress. Parathyroidectomy is es-
sential for treatment (1,2).
CASE REPORT
A 36-day-old female infant was brought to the health 
care service with dehydration, apathy, and lack of bre-
ast feeding. She presented severe hypercalcemia, hypo-
phosphatemia, high levels of PTH with normal renal 
function (Table 1). Chest X-ray showed a narrowed, 
bell-shaped rib cage (Figure 1). The baby underwent 
subtotal parathyroidectomy because she remained hi-
percalcemic despite of hydratation, furosemide and 
biphosphonate administration. At that moment, the 
diagnosis of NSHPT was suspected.
After two months, the infant returned to the Hos-
pital de Niños Pedro de Elizalde presenting hypercal-
cemia recurrence and a skin lesion which rapidly eva-
luated to sepsis. She was transferred to the intensive 
care unit where she received appropriate antibiotics and 
three doses of pamidronate to control hypercalcemia 
until a total parathyroidectomy was possible (Table 1 
and Figure 2).
The second surgery occurred when the patient was 
7 months of age and although the goal was to perma-
mnently correct hypercalcemia, her follow-up lab tests 
showed mild elevated serum calcium concentrations and 
inappropriately normal PTH levels, probably due to an 
extra numbered or remained parathyroid (Table 1).
Table 1. Lab evaluation of the index case
CA - 36 days 2 months 4 months 7 months 2-6 yrs
Condition Normal range 1st admission 2 weeks after
1st surgery
2 m after 
1st surgery
1 week after “total” 
PTx
After PTx
Ca (mg/dL) 8.8-10.8 18.1 8.0 19.2 10.6 11.1-12.4
Ca i (mg/dL) 4.8-5.5 10.6 - - - 6.1
P (mg/dL) 5.0-10.8 (< 1 yr)
3.4-6.2 (1-12 yr)
4.1 3.9 - 5.3 3.8-5.4
PTH (pg/mL) 11-62 1036 56 281 27 36-50
Cr (mg/dL) 0.2-0.4 (< 1 yr) 0.35 - - - 0.3-0.7
CA: chronological age; PTx: parathyroidectomy; Ca: total serum calcium; Ca i: ionized serum calcium; P: serum phosphate; Cr: serum creatinine.
Figure 1. Chest X-ray of the child showing a narrowed, bell-shaped rib 
cage; the top arrows indicate a probable healing of the rib fractures and the 
bottom one a callusing right rib fracture.
Nowadays, the child is 6 years old, 101 cm tall 
(SD -2.17), has normal bone age and she weighs 15.3 
kg (SD -2.06). For the last 3 years to date, her diet 
has been hypocalcemic (around 500 mg of calcium 
per day) and supplemented by 800 U/d of vitamin 
D. There was no sign of nephrocalcinosis at renal ul-
trasonography, neither was there any episode of bone 
fracture.
Her parents are healthy, asymptomatic for the di-
sease, denied medication intake, consanguinity or any 
similar case in the family. Almost all of their lab tests 
were normal, although measurement was done only 
once (Table 2).
In order to confirm in the baby NSHPT disease cau-
sed by a CASR loss-of-function, its coding region was 
analyzed from her genomic DNA. The parents’ geno-
mic DNAs were also studied with the aim of knowing if 
the child’s genetic condition was inherited or not.
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Figure 2. Lab evaluation of serum calcium (A) and PTH levels (B) of the index case. PM: pamidronate.
Table 2. Lab data of the patient’s parents
Analyte Normal range Father Mother
Ca (mg/dL) 8.6-10.2 9.9 9.4
Ca i (mg/dL) 4.7-5.3 - -
P (mg/dL) 2.3-4.6 3.8 3.3
PTH (pg/mL) 11-62 53.1 83.7
Cr (mg/dL) 0.5-0.9 (women)
0.7-1.2 (men)
0.8 0.6
Cl Ca/Cr (urine 24 h) - 0.014 0.02
25 OH-D (ng/mL) > 30 25.1 5.0
Ca: total serum calcium; Ca i: ionized serum calcium; P: serum phosphate; Cr: serum creatinine; 
Cl Ca/Cr: 24 h urinary calcium to creatinine clearance ratio (the cut-off value differentiating FHH 
from primary hyperparathyroidism is 0.01); 25 OH-D: 25 hydroxy-vitamin D.
METHODS AND RESULTS
The study protocol was approved by the Ethics Com-
mittee, and informed consent was obtained from the 
parents. Genomic DNA was extracted from peripheral 
blood leukocytes from the patient and her parents. Ten 
intronic primer pairs were used to amplify exons 2–7 
from the CASR gene, which encode the CASR protein. 
After amplification confirmation by electrophoresis in 
agarosis gel, PCR products were submitted to auto-
matic sequencing reaction. A homozygous mutation 
(p.E519X) was identified at exon 5 of CASR in the 
DNA of the index case. Both mother and father had the 
same mutation in heterozygous state (Figures 3 and 4).
DISCUSSION AND CONCLUSIONS
Although NSHPT is a rare disease the survival of chil-
dren depends on early diagnosis and appropriate treat-
ment, usually involving parathyroidectomy (3). In this 
case, it was decided to perform a subtotal parathyroi-
dectomy because the family belongs to a native Indian 
community located far from a any health care service 
and hypocalcemia after total parathyroidectomy could 
be more deleterious than mild hypercalcemia. Howe-
ver, follow-up of this case showed quick relapse with 
severe clinical repercussions and a second surgery was 
necessary to control hypercalcemia.
The molecular basis of NSHPT is a lack of CASR 
function that can be inherited (in this situation, it was 
expected that the parents were FHH) or secondary to 
de novo mutation.
FHH is characterized by a persistent, non-progres-
sive mild to moderate hypercalcemia, relative hypocal-
ciuria, and absence of classical clinical features of prima-
ry hyperparathyroidism (PHTP). Besides the suspected 
diagnosis after routine biochemical screening showing 
high blood calcium levels, another hint of FHH is the 
persistence or recurrence of hypercalcemia after surgical 
treatment of PHPT in members of the same kindred 
(4). It is a benign condition in which the patients may 
have nonspecific symptoms such as fatigue, weakness, 
painful joints, and headache.
In this case, even though the child’s parents had 
normal levels of total calcium we do not know the va-
lues of ionized calcium neither the values of calcium 
albumin-adjusted. Moreover there was only one mea-
surement for each individual.
Generally, PTH levels in FHH are not suppressed 
by hypercalcemia and are inappropriately normal. In a 
family studied by Zajickova and cols. it was demonstra-
ted that the vitamin D deficiency of proband, determi-
ned high levels of PTH which were normalized after 
vitamin D repletion (5). In this family, at first glance, 
the mother’s PTH suggests secondary hyperparathyroi-
dism but, as she has FHH, probably her vitamin D re-
placement should result in hypercalcemia with PTH in 
the upper limit. In other words, her normocalcemia 
could be underestimated by vitamin D deficiency.
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Figure 3. Electropherogram of CASR exon 5 fragment; the arrow points to nucleotide 1993 and the box shows the codon 519. (A) Wild type sample. (B) 
Proband: substitution G → T in homozigous state. (C) Proband’s father: substitution G → T in heterozigous state. (D) Proband’s mother: substitution G → 
T in heterozigous state.
Figure 4. (A) Pedigree of the family. CASR molecular analysis of the sister and the brother of the proband was not performed. (B) CASR protein showing its 
extracellular, transmembrane and intracellular domains; the arrow points to the 519 amin oacid adapted from Rodriguez and cols. (6).
To assess relative hypocalciuria, the ratio of renal 
calcium clearance to creatinine clearance (Cl Ca/Cr) is 
determined classically. In hypercalcemic cases, this cle-
arance ratio in FHH averages one third of that found 
in typical PHPT and a cut-off value < 0.01 is helpful 
for diagnosis. This index was based on meta-analysis 
showing a sensitivity of 81% for diagnosing FHH, 
with a specificity of 88% for excluding PHPT (4). Our 
patient’s parents disclosed normal ratios of Cl Ca/Cr 
(Table 2). Thus, based exclusively on their lab data, 
hardly a FHH hypothesis could be considered.
The presence of p.E519X mutation in the CASR 
of the infant patient, in homozygous state, justifies the 
NSHPT phenotype. The same mutation in her parents’ 
DNAs, in heterozygous, revealed the diagnosis of FHH 
and surprisingly confirmed its inherited origin. Even if 
the parents denied consanguinity, the fact of belonging 
to a restricted community in Argentina’s southwestern 
(Mapuche tribe) suggests blood relationship.
When the study was being carried out the couple had 
another child who died in early infancy after presenting si-
milar symptoms of the index case, probably in consequen-
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ce of hypercalcemia. On the other hand, calcium metabo-
lism of the sister child was only performed recently and no 
abnormalities were found; her Cl Ca/Cr ratio is 0.06 (Fi-
gure 3). Although late, the results of this research enable 
genetic counseling for future cases of NSHPT or FHH.
The p.E519X mutation in the CASR has not been 
previously described and although it has not been done 
an in vitro study we believe it is the cause of NSHPT 
phenotype in our patient and of the FHH in her pa-
rents because the substitution of guanine by thymine 
at nucleotide 1993 of the CASR gene predicts a stop 
codon at 519 aa resulting in a truncated and inactive 
protein as consequence of loss of the full transmembra-
ne and intracellular domains (Figure 4).
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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